Atripla is an antiretroviral medication owned by Gilead Sciences. It contains Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate as its active ingredients. First marketed on 12 July, 2006, it has been patented seven times, none of which have expired yet.
The availability of Atripla generic is expected after 28 April, 2029, which aligns with the expiry date of its last patent.
Atripla is used in the treatment of HIV-1 infection in both adults and pediatric patients 12 years of age and older. It works by combining three antiretroviral agents that inhibit the growth of the virus thus helping to control the infection.
Atripla's patents focus on its unique combination antiviral therapy and its unitary pharmaceutical dosage form. The last Atripla generic patent is expected to expire on 28 April, 2029. Below are the details of the patents: